Mural Oncology plc (MURA)
NASDAQ: MURA · Real-Time Price · USD
3.520
-0.100 (-2.76%)
Nov 12, 2024, 4:00 PM EST - Market closed
Company Description
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Mural Oncology plc
Country | Ireland |
Founded | 2013 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 117 |
CEO | Caroline Loew |
Contact Details
Address: 10 Earlsfort Terrace Dublin, D02 T380 Ireland | |
Phone | 353 1 905 8020 |
Website | muraloncology.com |
Stock Details
Ticker Symbol | MURA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001971543 |
ISIN Number | IE000LK2BOB4 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Caroline J. Loew Ph.D. | President, Chief Executive Officer and Director |
Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
Maiken Keson-Brookes | Chief Legal Officer |
Justin Levine | Head of Human Resources and Vice President of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 8, 2024 | 144 | Filing |
Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 1, 2024 | 144 | Filing |
Sep 26, 2024 | 8-K | Current Report |
Sep 23, 2024 | 8-K | Current Report |
Aug 13, 2024 | SCHEDULE 13G | Filing |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 13, 2024 | 8-K | Current Report |
Aug 5, 2024 | 8-K | Current Report |